Akeso’s ivonescimab hits overall survival secondary endpoint in interim Harmoni-2
Akeso Inc (9926) says interim Phase III Harmoni-2 analysis met overall survival as a key secondary endpoint, showing statistically significant and clinically meaningful benefit versus pembrolizumab in first-line PD-L1-positive NSCLC.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.